Back to search results

Understanding Fat Tissue Response in Obesity

This study is looking for 24 adults, aged 18-65, to help researchers understand why fat tissue responds differently in people with different body types, especially those who carry more weight around their belly. You might be eligible if you are overweight or obese (BMI 29-40). The study will test how fat cells release free fatty acids (FFA) after receiving intravenous infusions of Somatostatin and Epinephrine. Researchers will measure FFA release from fat tissue in different body areas to see how these drugs affect fat cells. The goal is to understand what "turns on" fat cells in people with and without obesity. The current recruitment status is unclear.

Study design
This interventional study plans to enroll 24 participants. It will investigate how fat cells respond to specific drug infusions.
What's involved
You would need to eat an exact diet provided by the Mayo Clinical Research and Trials Unit for at least 3 days before the study. The study involves receiving intravenous infusions of Somatostatin and Epinephrine, and measurements of free fatty acid release will be taken for approximately 3.5 hours.
Compensation
Not stated in the trial record.
Follow-up
Measurements will be taken at approximately 3.5 hours after the interventions. No further follow-up is specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06416969

Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Recruiting
EARLY_PHASE1Ages 18–65InterventionalBasic science
Mayo Clinic
~24 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:SomatostatinEpinephrine

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Free Fatty Acid (FFA) release from femoral, splanchnic and upper body subcutaneous adipose tissue
Measured over approximately 3.5 hours
+1 more outcome measured

Conditions

Obesity

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Michael Jensen, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Madeline Reid
[email protected]
(507) 255-6062
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males and females between 18 and 65 years of age who are able to comprehend instructions, follow study procedures, willing to sign an informed consent form, and consume an isoenergetic diet eating all meals from Mayo Clinical Research and Trials Unit for at least 3 days prior to study.
Overweight/Obese volunteers will have a BMI 29.0 - 40.0 kg/m2
Female subjects are eligible if they meet the following criteria:
Are not pregnant or nursing
All women of childbearing potential will have a negative urine pregnancy test at screening and a negative urine pregnancy test within 48 hours before administering study drug.
Recent or current research participation in a study that involves an investigational drug. Participants in other clinical trials that involve an investigational drug will not be able to participate in this study until 12 weeks after their participation in the other study is complete or \> than five half-lives of the compound, whichever is longer. If Yes look at consent form and f/u visits:
Current use of medications that alter fatty acid or adipose metabolism possibly given: if yes, exclude
Amount of blood drawn during the study (if our study plus this one draw ≥ 450 ml these should be separated by 8 weeks
Previous labs:
Fasting glucose \< 126 mg/dl for non-diabetic UBO
Hb ≥ 11.0 for women and ≥ 12 for men
platelets \> 100 000

Exclusion

Individuals with a history of a disease process such as:
Ischemic heart disease
Atherosclerotic valvular disease
Persistent blood pressure greater than 160/95 despite antihypertensive medication
Peripheral artery disease
Any history of trans-ischemic attacks.
Coronary artery disease.
Liver cirrhosis
Significant renal impairment as documented in medical chart.
Smokers
Diagnosis of Diabetes Mellitus.
Concomitant use of medications that can alter free fatty acid metabolism or pose a drug-drug interaction: statins (if yes hold for 4 weeks and receive primary care provider's approval); Niacin; Fibrates; thiazolidinedione; Beta-blockers; Oral or injected corticosteroids or anabolic steroids; Linezolid; Dihydroergotamine; Phenelzine; daily phosphodiesterase inhibitors
Allergy to lidocaine
Allergy to indocyanine green.

What this trial measures

  • Free Fatty Acid (FFA) release from femoral, splanchnic and upper body subcutaneous adipose tissueapproximately 3.5 hours

    regional palmitate release rates (micromol/min) will be measured using a combination of leg and splanchnic blood flow combined with stable isotope tracer measurements of palmitate uptake and release across the leg and splanchnic bed. Upper body, non-splanchnic palmitate release will be calculated as: total palmitate release - (splanchnic palmitate release + (leg palmitate release x 2)). Release rates will be measured at baseline (overnight fasting) and in response to the infusion of somatostatin plus epinephrine. This will allow us to understand the factors that may limit maximum lipolysis stimulation in upper body obesity for leg, splanchnic and upper body non-splanchnic adipose tissue palmitate release.

  • stimulated FFA release in volunteers with and without obesity.approximately 3.5 hours

    we will measure whether stimulated adipose tissue lipolysis from infusions of somatostatin and epinephrine is impaired in UBO and, if so, if this is related to regional differences in lipolysis and lipolysis-regulating proteins;